154 related articles for article (PubMed ID: 36974676)
1. The effectiveness and safety of oral medications, onabotulinumtoxinA (three doses) and transcutaneous tibial nerve stimulation as non or minimally invasive treatment for the management of neurogenic detrusor overactivity in adults: a systematic review and network meta-analysis.
Chen Y; Peng L; Zhang C; Chen J; Chen J; Shen H; Luo D
Int J Surg; 2023 May; 109(5):1430-1438. PubMed ID: 36974676
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis.
Xu R; Yang TX; Fang KW; Wang G; Li P
Sci Rep; 2022 Oct; 12(1):17905. PubMed ID: 36289427
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
4. Detrusor relaxing agents for neurogenic detrusor overactivity: a systematic review, meta-analysis and network meta-analysis.
Zhou Z; Wang X; Li X; Liao L
BJU Int; 2024 Jan; 133(1):25-33. PubMed ID: 37500569
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.
Soljanik I
Drugs; 2013 Jul; 73(10):1055-66. PubMed ID: 23775527
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Cheng T; Shuang WB; Jia DD; Zhang M; Tong XN; Yang WD; Jia XM; Li S
PLoS One; 2016; 11(7):e0159307. PubMed ID: 27463810
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
9. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
10. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Honda M; Yokoyama O; Takahashi R; Matsuda T; Nakayama T; Mogi T
Int J Urol; 2021 Sep; 28(9):906-912. PubMed ID: 34075630
[TBL] [Abstract][Full Text] [Related]
12. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
13. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.
Chancellor MB; Patel V; Leng WW; Shenot PJ; Lam W; Globe DR; Loeb AL; Chapple CR
Neurology; 2013 Aug; 81(9):841-8. PubMed ID: 23892704
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review.
Zhang R; Xu Y; Yang S; Liang H; Zhang Y; Liu Y
Int Braz J Urol; 2015; 41(2):207-19. PubMed ID: 26005961
[TBL] [Abstract][Full Text] [Related]
16. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
17. Effects of Bilateral Transcutaneous Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Spinal Cord Injury: A Urodynamic Study.
Kamboonlert K; Panyasriwanit S; Tantisiriwat N; Kitisomprayoonkul W
Arch Phys Med Rehabil; 2021 Jun; 102(6):1165-1169. PubMed ID: 33245938
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
[TBL] [Abstract][Full Text] [Related]
19. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.
Przydacz M; Golabek T; Chlosta P
Adv Clin Exp Med; 2019 Apr; 28(4):555-567. PubMed ID: 30729759
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.
Zhou X; Yan HL; Cui YS; Zong HT; Zhang Y
Chin Med J (Engl); 2015 Apr; 128(7):963-8. PubMed ID: 25836619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
